Postavení ustekinumabu v léčbě Crohnovy nemoci
| Authors | |
|---|---|
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapeutická revue |
| MU Faculty or unit | |
| Citation | |
| Web | https://farmakoterapeutickarevue.cz/cs/postaveni-ustekinumabu-v-lecbe-crohnovy-nemoci |
| Keywords | Crohn's disease; biologic treatment; ustekinumab |
| Description | Crohn's disease is a multifactorial condition, a life-long inflammatory disease of the gastrointestinal tract with unknown etiology and a partially elucidated pathogenesis. Crohn's disease causal treatment is still unavailable. Conventional immunosuppressive therapy has been extended over the last 20 years by biological treatment with monoclonal antibodies. TNFa inhibitors were the first biological drugs used in the treatment of inflammatory bowel disease. The high initial therapeutic efficacy of these products is burdened by some of the side effects and complications that are forced to end in some patients. A promising and well tolerated treatment alternative for Crohn's disease patients, with moderate and severe disease activity, is the new fully human monoclonal antibody ustekinumab. The mechanism of action of the ustekinumab is based on the inhibition of the biological activity of IL-12/IL-23. Ustekinumab is indicated and approved by international and Czech authorities for induction and maintenance treatment of Crohn's disease patients who are resistant or intolerant and/or have contraindications for conventional immunosuppressive therapy and/or treatment of TNFa inhibitors. |